Article

Daily Medication Pearl: Ganciclovir Injection

Ganciclovir injection is a nucleoside analogue cytomegalovirus DNA polymerase inhibitor.

Medication Pearl of the Day: Ganciclovir Injection

Indication: Ganciclovir injection is a nucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for the treatment of CMV retinitis in immunocompromised adult patients, including patients with AIDS; prevention of CMV disease in adult transplant recipients at risk for CMV disease.

Insight:

  • Dosing: 5 mg/kg every 12 hours.
  • Dosage forms: Injection 500 mg ganciclovir in 250 mL (2 mg per mL) solution in a single-dose bag for intravenous use.
  • Adverse events: Most common adverse reactions and laboratory abnormalities reported in at least 20% of patients were fever, diarrhea, leukopenia, anemia, catheter related events (including catheter infection and catheter sepsis), and elevated creatinine levels.
  • Mechanism of action: Ganciclovir is an antiviral drug with activity against CMV.

Source: GANCICLOVIR INJECTION Label (fda.gov)

Related Videos
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
Pharmacy, Advocacy, Opioid Awareness Month | Image Credit: pikselstock - stock.adobe.com
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Hurricane Helene, Baxter plant, IV fluids shortage, health systems impact, injectable medicines, compounding solutions, patient care errors, clinical resources, operational consideration, fluid conservation, sterile water, temperature excursions, training considerations, patient safety, feedback request
Image Credit: © peopleimages.com - stock.adobe.com
Pharmacists, Education, Advocacy, Opioid Awareness Month | Image Credit: Jacob Lund - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards